BSE · 540729
Vanta Bioscience Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹2 Cr with net profit ₹-5 Cr — a -230.19% net margin, versus -23.56% the period before.
Shareholding
As of 2026-03-31
- Promoter72.81%
- Public27.19%
426 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.97× from low to high.
Risk flags
Derived from disclosed data
- Under exchange surveillance — ESM · ESM 1. Trading may carry price bands, periodic call auction or higher margins.
Peer comparison
Miscellaneous · ranked #310 of 530 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Adani Ports & Special Economic Zone Ltd. | ₹3,96,212 Cr | 119.01 | 4.12 | 13.32% | 33.06% |
| Eternal Limited | ₹3,00,898 Cr | 1641.05 | 9.25 | 1.18% | 0.67% |
| BSE Limited | ₹1,44,241 Cr | 183.02 | 21.65 | 37.42% | 51.66% |
| GAIL (India) Ltd. | ₹1,15,143 Cr | 77.49 | 1.29 | 8.51% | 5.34% |
| GMR Airports Limited | ₹1,13,087 Cr | 369.31 | — | -10.6% | 1.19% |
| Mazagon Dock Shipbuilders Ltd. | ₹93,092 Cr | 137.04 | 9.54 | 26.48% | 21.23% |
| One 97 Communications Ltd. | ₹85,165 Cr | 463.41 | 5.31 | 4.55% | 6.55% |
| Meesho Limited | ₹82,526 Cr | — | 18.67 | -28.13% | -10.75% |
| Info Edge (India) Ltd. | ₹80,913 Cr | 142.94 | 2.13 | 3.82% | 0.44% |
| Swiggy Limited | ₹79,315 Cr | — | 4.33 | -22.68% | -18.02% |
| Vanta Bioscience Limited(this company) | ₹18 Cr | 168.6 | 0.85 | 0.51% | 0% |
AI analysis
AI-generated · google/gemini-2.5-flashVanta Bioscience Limited is listed with a market capitalization of Rs 18 Cr. The company reported revenue of Rs 2.07 Cr and a negative profit margin of 0%. The price to earnings ratio stands at 168.6, with an EPS of Rs 0.15.
Positives
- +Promoter shareholding is 72.81% as of March 2026, indicating significant control.
- +No promoter shares are reported as pledged.
Negatives
- −The company reported a negative profit margin of 0%.
- −Debt-to-equity ratio is high at 5.11, indicating substantial leverage.
- −Revenue decreased from Rs 9.83 Cr in March 2024 to Rs 2.07 Cr in March 2025.
- −Net profit has been negative for the past four reported annual periods, reaching -Rs 4.77 Cr in March 2025.
- −The company is under ESM 1 surveillance.
Financial Performance
Vanta Bioscience Limited's revenue for the fiscal year ending March 2025 was Rs 2.07 Cr. This marks a decrease from Rs 9.83 Cr in March 2024. The company reported a net profit of -Rs 4.77 Cr for the same period, compared to -Rs 2.32 Cr in March 2024. The EPS for March 2025 was -Rs 7.56.
Profitability & Returns
The company's profitability as measured by profit margin was 0%. Return on equity (ROE) was 51.1% and return on capital employed (ROCE) was 1.31%. Earnings per share (EPS) for the latest period was Rs 0.15. The EBITDA for March 2025 was -Rs 8.56 Cr.
Balance Sheet
The debt-to-equity ratio for Vanta Bioscience Limited is 5.11, indicating a high level of debt relative to equity. The book value per share stands at Rs 29.77.
Ownership & Pledges
As of March 31, 2026, the promoter holding in Vanta Bioscience Limited was 72.81%. Public shareholding was 27.19%. There was no reported pledge of promoter shares. There were 426 shareholders in March 2026.
Regulatory & Surveillance
Vanta Bioscience Limited is under ESM (Enhanced Surveillance Measure) Stage 1, indicating increased scrutiny from the exchanges. This measure typically involves additional reporting and trading restrictions.
Data as of — price: 2026-07-29 · financials: Mar 25 · shareholding: Mar 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.